Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immedica AB
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Impilo AB, Medical Need Europe AB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.